Elastase
Elastase is a group of serine proteases that include the macrophage elastase, the fibroblast elastase, the neutrophil elastase, and the pancreatic elastase. Elastase can not only cleave the important connective tissue protein elastin, but also facilitate the degradation of the extracellular matrix such as fibronectin; laminin; collagens III, IV, and VI; and proteoglycans.
Mammalian elastases occur mainly in the pancreas and the phagocytes. Among non-mammalian elastases there is a great variety of bacterial metallo and serine elastases. The elastolytic activity varies from one elastase to another and is usually not correlated with the catalytic efficiency of these proteinases. There is a large number of natural (proteins) and synthetic elastase inhibitors. Elastases play a pathologic role in pulmonary emphysema, cystic fibrosis, infections, inflammation, and atherosclerosis.
All Product Categories
-
Elastase Related Products (107)
Related Products (107)
-
MDL27324
0 ImagesCat. No.: HY-126822CAS No.: 123285-50-7MDL27324 is an inhibitor of neutrophil proteases. MDL27324 can be taken up by the cell and has a modest inhibitory effect on the proteolysis of ingested fluoresceinated immune complexes (200 μM, 20% inhibition).
-
L 708286
0 ImagesCat. No.: HY-118293CAS No.: 119720-81-9Synonyms: DFKiL 708286 (DFKi) is a slow-binding inhibitor of human leukocyte elastase (HLE). L 708286 is a peptide-based phenethylcarbamoyl difluoromethylene compound. L 708286 can be used in the study of respiratory diseases.
-
LasB-IN-3
0 ImagesCat. No.: HY-181647CAS No.: 2762675-42-1LasB-IN-3 is a protease elastase (LasB) inhibitor of Pseudomonas aeruginosa with an IC50 value of 8.5 nM. LasB-IN-3 shows an IC50 of 58.9 nM for the Met128Val mutant. LasB-IN-3 binds to active sites of wild-type and Met128Val mutant LasB, coordinates zinc ions, forms hydrogen bonds and CH-π interactions, and inhibits LasB proteolytic activity. LasB-IN-3 increases survival rate in LasB-induced acute lung injury mice models. LasB-IN-3 can be used for the research of Pseudomonas aeruginosa infection.
-
Sivelestat (Standard)
0 ImagesSynonyms: EI546 (Standard); LY544349 (Standard); ONO5046 (Standard)Sivelestat (Standard) is the analytical standard of Sivelestat. This product is intended for research and analytical applications. Sivelestat (EI546) is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
-
BAY-677 (Standard)
0 ImagesCat. No.: HY-111457RCAS No.: 2117404-84-7BAY-677 (Standard) is the analytical standard of BAY-677 (HY-111457). This product is intended for research and analytical applications. BAY-677 is an inactive control for BAY-678. BAY-678 is an orally bioavailable, highly potent, selective and cell-permeable inhibitor of human neutrophil elastase (HNE), with an IC50 of 20 nM. BAY-678 is also nominated as a chemical probe to the public via the Structural Genomics Consortium (SGC).
-
Sivelestat sodium tetrahydrate (Standard)
0 ImagesSynonyms: EI546 sodium tetrahydrate (Standard); LY544349 sodium tetrahydrate (Standard); ONO5046 sodium tetrahydrate (Standard)Sivelestat (sodium tetrahydrate) (Standard) is the analytical standard of Sivelestat (sodium tetrahydrate). This product is intended for research and analytical applications. Sivelestat (EI546) sodium tetrahydrate is a competitive inhibitor of human neutrophil elastase, with an IC50 of 44 nM and a Ki of 200 nM. Sivelestat (EI546) sodium tetrahydrate has the potential for the study of acute lung injury/acute respiratory distress syndrome or disseminated intravascular coagulation in COVID-19.
-
L 684248
0 ImagesCat. No.: HY-117591CAS No.: 156728-18-6L-684248 is an inhibitor of human leukocyte elastase (HLE). L-684248 exerts its inhibitory effect on HLE by forming a covalent bond with the active site of the enzyme, showing potential value for applications in anti-inflammatory and anti-tumor research.
